A detailed thermodynamic profile of cyclopentyl and isopropyl derivatives binding to CK2 kinase
The detailed understanding of the molecular features of a ligand binding to a target protein, facilitates the successful design of potent and selective inhibitors. We present a case study of ATP-competitive kinase inhibitors that include a pyradine moiety. These compounds have similar chemical structure, except for distinct terminal hydrophobic cyclopentyl or isopropyl groups, and block kinase activity of casein kinase 2 subunit α (CK2α), which is a target for several diseases, such as cancer and glomerulonephritis. Although these compounds display similar inhibitory potency against CK2α, the crystal structures reveal that the cyclopentyl derivative gains more favorable interactions compared with the isopropyl derivative, because of the additional ethylene moiety. The structural observations and biological data are consistent with the thermodynamic profiles of these inhibitors in binding to CK2α, revealing that the enthalpic advantage of the cyclopentyl derivative is accompanied with a lower entropic loss. Computational analyses indicated that the relative enthalpic gain of the cyclopentyl derivative arises from an enhancement of a wide range of van der Waals interactions from the whole complex. Conversely, the relative entropy loss of the cyclopentyl derivative arises from a decrease in the molecular fluctuation and higher conformational restriction in the active site of CK2α. These structural insights, in combination with thermodynamic and computational observations, should be helpful in developing potent and selective CK2α inhibitors.
KeywordsCK2 Isothermal titration calorimeter Crystal structure Molecular dynamics Entropy/enthalpy compensation
These studies are supported by the Program of Fundamental Studies in Health Science of the National Institute of Biochemical Innovation (NIBIO). The synchrotron radiation experiments were done at the BL6A and BL17A stations in the Photon Factory, and at the BL44XU station in SPring-8 faculty with MX225-HE (Rayonix), which is financially supported by Academia Since and National Synchrotron Radiation Research Center (Taiwan, ROC).
- 3.Terasaka T, Ohkumura H, Tsuji K, Kato T, Nakanishi I, Kinoshita T, Kato Y, Kuno M, Seki N, Naoe Y, Inoue T, Tanaka K, Nakamura K (2004) Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors. J Med Chem 47:2728–2731PubMedCrossRefGoogle Scholar
- 12.Yamada M, Katsuma S, Adachi T, Hirasawa A, Shiojima S, Kadowaki T, Okuno Y, Koshimizu TA, Fujii S, Sekiya Y, Miyamoto Y, Tamura M, Yumura W, Nihei H, Kobayashi M, Tsujimoto G (2005) Inhibition of protein kinase CK2 prevents the progression of Glomerulonephritis. Proc Natl Acad Sci USA 102:7736–7741PubMedCrossRefGoogle Scholar
- 13.Cozza G, Bonvini P, Zorzi E, Poletto G, Pagano MA, Sarno S, Sonellaa-Deana A, Zagotto G, Rosolen A, Pinna LA, Meggio F, Moro S (2006) Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem 49:2363–2366PubMedCrossRefGoogle Scholar
- 20.Nie Z, Perretta C, Erickson P, Margosiak S, Lu J, Averill A, Almassy R, Chu S (2008) Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a][1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities. Bioorg Med Chem Lett 18:619–623PubMedCrossRefGoogle Scholar
- 25.Otwinoski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Method in enzymology, vol 276. Academic press, New York, pp 307–326Google Scholar
- 30.Halgren TA, Nachbar RB (1996) Merck molecular force field. IV. Conformational energies and geometries for MMFF94. J Comput Chem 17:587–615Google Scholar
- 43.Liu C, Wrobleski ST, Lin J, Ahmed G, Metzger A, Wityak J, Gillooly KM, Shuster DJ, McIntyre KW, Pitt S, Shen DR, Zhang RF, Zhang H, Doweyko AM, Diller D, Henderson I, Barrish JC, Dodd JH, Schieven GL, Leftheris K (2005) 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38a MAP kinase. J Med Chem 48:6261–6270PubMedCrossRefGoogle Scholar